US firm's noninvasive stomach stapling technique shows early promise
This article was originally published in Clinica
To capitalise on the growing obesity problem worldwide, venture capitalists have eagerly poured money into a handful of upstart companies developing the next new thing in weight loss surgery.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.